THERMO FISHER SCIENTIFIC INC
TMONYSETrading Snapshot
- Day Range
- $601.30 – $614.46
- 52-Week Range
- $435.27 – $643.99
- Volume
- $7.01B
- Avg Volume
- $7.07B
- Shares Outstanding
- 371.6M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $46.82B
- Last Q Revenue
- $12.44B
- P/E Ratio
- 31.5
- P/S Ratio
- 4.7x
- EPS (TTM)
- $18.57
- Dividend Yield
- 0.30%
Why Investors Own TMO
- ✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About THERMO FISHER SCIENTIFIC INC
A company profile for THERMO FISHER SCIENTIFIC INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Thermo Fisher Says India Is One Of Its Fastest-Growing Markets
Thermo Fisher expects 15-20% customer growth in India over 5 years, driven by expanding biopharma, clean energy, and tech sectors.
Witnessing An Insider Decision, Joseph R Holmes Exercises Options Valued At $120K At Thermo Fisher Scientific
A significant insider transaction involving the exercise of company stock options was reported on August 10, by Joseph R Holmes, VP & Chief Accounting Officer at Thermo Fisher Scientific (NYSE:TMO), as per the
Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific
Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market gr
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and th
How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform
In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B·R·A·H·M·S, Thermo Fisher is...
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State